Its selective GH release without cortisol, prolactin, or appetite effects makes it better tolerated, more practical for sustained use, and the preferred GHRP partner for combination protocols with GHRH analogs
Understanding these differences helps clarify why compounded formulations are likely to remain available even if branded markets shift
What are the main formulation challenges in oral peptide development
*Correspondence: Na Ren, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
128 Again, the changes in these parameters were moderate, as was the injury, and the conclusions were based on correlations between injury and non-specific parameters
The table below highlights the key differences